{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:46:22Z","timestamp":1771512382484,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.medcli.2025.107185","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:31:18Z","timestamp":1758735078000},"page":"107185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of tocilizumab as a therapeutic option for hereditary apolipoprotein AI-associated amyloidosis"],"prefix":"10.1016","volume":"165","author":[{"given":"Luis","family":"Luque Caraballo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Garrido Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Salvador","family":"Garc\u00eda Morillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107185_bib0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13506129.2022.2070741","article-title":"The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre","volume":"29","author":"Cohen","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2025.107185_bib0010","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026843","article-title":"Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: case report and review of literature","volume":"100","author":"Jung","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.medcli.2025.107185_bib0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/14397595.2018.1515145","article-title":"AA amyloidosis \u2013 benefits and prospects of IL-6 inhibitors","volume":"29","author":"Okuda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.medcli.2025.107185_bib0020","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107185_bib0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12881-019-0755-5","article-title":"A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options","volume":"20","author":"Moutafi","year":"2019","journal-title":"BMC Med Genet"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325004130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:44:50Z","timestamp":1771508690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325004130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0025775325004130"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107185","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of tocilizumab as a therapeutic option for hereditary apolipoprotein AI-associated amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107185"}}